250 related articles for article (PubMed ID: 16012945)
1. The Ras effector RASSF2 is a novel tumor-suppressor gene in human colorectal cancer.
Akino K; Toyota M; Suzuki H; Mita H; Sasaki Y; Ohe-Toyota M; Issa JP; Hinoda Y; Imai K; Tokino T
Gastroenterology; 2005 Jul; 129(1):156-69. PubMed ID: 16012945
[TBL] [Abstract][Full Text] [Related]
2. Correlation between hypermethylation of the RASSF2A promoter and K-ras/BRAF mutations in microsatellite-stable colorectal cancers.
Park HW; Kang HC; Kim IJ; Jang SG; Kim K; Yoon HJ; Jeong SY; Park JG
Int J Cancer; 2007 Jan; 120(1):7-12. PubMed ID: 17013898
[TBL] [Abstract][Full Text] [Related]
3. Genetic and epigenetic alterations of Ras signalling pathway in colorectal neoplasia: analysis based on tumour clinicopathological features.
Harada K; Hiraoka S; Kato J; Horii J; Fujita H; Sakaguchi K; Shiratori Y
Br J Cancer; 2007 Nov; 97(10):1425-31. PubMed ID: 17923875
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic inactivation of the RAS-effector gene RASSF2 in lung cancers.
Kaira K; Sunaga N; Tomizawa Y; Yanagitani N; Ishizuka T; Saito R; Nakajima T; Mori M
Int J Oncol; 2007 Jul; 31(1):169-73. PubMed ID: 17549418
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic regulation of the ras effector/tumour suppressor RASSF2 in breast and lung cancer.
Cooper WN; Dickinson RE; Dallol A; Grigorieva EV; Pavlova TV; Hesson LB; Bieche I; Broggini M; Maher ER; Zabarovsky ER; Clark GJ; Latif F
Oncogene; 2008 Mar; 27(12):1805-11. PubMed ID: 17891178
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic inactivation of RASSF2 in oral squamous cell carcinoma.
Imai T; Toyota M; Suzuki H; Akino K; Ogi K; Sogabe Y; Kashima L; Maruyama R; Nojima M; Mita H; Sasaki Y; Itoh F; Imai K; Shinomura Y; Hiratsuka H; Tokino T
Cancer Sci; 2008 May; 99(5):958-66. PubMed ID: 18294275
[TBL] [Abstract][Full Text] [Related]
7. CpG island promoter hypermethylation of a novel Ras-effector gene RASSF2A is an early event in colon carcinogenesis and correlates inversely with K-ras mutations.
Hesson LB; Wilson R; Morton D; Adams C; Walker M; Maher ER; Latif F
Oncogene; 2005 Jun; 24(24):3987-94. PubMed ID: 15806169
[TBL] [Abstract][Full Text] [Related]
8. Colorectal cancer and RASSF family--a special emphasis on RASSF1A.
Fernandes MS; Carneiro F; Oliveira C; Seruca R
Int J Cancer; 2013 Jan; 132(2):251-8. PubMed ID: 22733432
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic silencing of diacylglycerol kinase gamma in colorectal cancer.
Kai M; Yamamoto E; Sato A; Yamano HO; Niinuma T; Kitajima H; Harada T; Aoki H; Maruyama R; Toyota M; Hatahira T; Nakase H; Sugai T; Yamashita T; Toyota M; Suzuki H
Mol Carcinog; 2017 Jul; 56(7):1743-1752. PubMed ID: 28218473
[TBL] [Abstract][Full Text] [Related]
10. Frequent inactivation of axon guidance molecule RGMA in human colon cancer through genetic and epigenetic mechanisms.
Li VS; Yuen ST; Chan TL; Yan HH; Law WL; Yeung BH; Chan AS; Tsui WY; So S; Chen X; Leung SY
Gastroenterology; 2009 Jul; 137(1):176-87. PubMed ID: 19303019
[TBL] [Abstract][Full Text] [Related]
11. K-ras mutations and RASSF1A promoter methylation in colorectal cancer.
van Engeland M; Roemen GM; Brink M; Pachen MM; Weijenberg MP; de Bruïne AP; Arends JW; van den Brandt PA; de Goeij AF; Herman JG
Oncogene; 2002 May; 21(23):3792-5. PubMed ID: 12032847
[TBL] [Abstract][Full Text] [Related]
12. IGFBP7 is a p53-responsive gene specifically silenced in colorectal cancer with CpG island methylator phenotype.
Suzuki H; Igarashi S; Nojima M; Maruyama R; Yamamoto E; Kai M; Akashi H; Watanabe Y; Yamamoto H; Sasaki Y; Itoh F; Imai K; Sugai T; Shen L; Issa JP; Shinomura Y; Tokino T; Toyota M
Carcinogenesis; 2010 Mar; 31(3):342-9. PubMed ID: 19638426
[TBL] [Abstract][Full Text] [Related]
13. RASSF2 is a novel K-Ras-specific effector and potential tumor suppressor.
Vos MD; Ellis CA; Elam C; Ulku AS; Taylor BJ; Clark GJ
J Biol Chem; 2003 Jul; 278(30):28045-51. PubMed ID: 12732644
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic silencing of CHD5, a novel tumor-suppressor gene, occurs in early colorectal cancer stages.
Fatemi M; Paul TA; Brodeur GM; Shokrani B; Brim H; Ashktorab H
Cancer; 2014 Jan; 120(2):172-80. PubMed ID: 24243398
[TBL] [Abstract][Full Text] [Related]
15. EYA4 Acts as a New Tumor Suppressor Gene in Colorectal Cancer.
Kim SJ; Tae CH; Hong SN; Min BH; Chang DK; Rhee PL; Kim JJ; Kim HC; Kim DH; Kim YH
Mol Carcinog; 2015 Dec; 54(12):1748-57. PubMed ID: 25620232
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of DLC-1 gene by promoter methylation during primary colorectal cancer progression.
Peng H; Long F; Wu Z; Chu Y; Li J; Kuai R; Zhang J; Kang Z; Zhang X; Guan M
Biomed Res Int; 2013; 2013():181384. PubMed ID: 23509688
[TBL] [Abstract][Full Text] [Related]
17. RASSF2 methylation is a strong prognostic marker in younger age patients with Ewing sarcoma.
Gharanei S; Brini AT; Vaiyapuri S; Alholle A; Dallol A; Arrigoni E; Kishida T; Hiruma T; Avigad S; Grimer R; Maher ER; Latif F
Epigenetics; 2013 Sep; 8(9):893-8. PubMed ID: 23887284
[TBL] [Abstract][Full Text] [Related]
18. The Ras effector RASSF2 controls the PAR-4 tumor suppressor.
Donninger H; Hesson L; Vos M; Beebe K; Gordon L; Sidransky D; Liu JW; Schlegel T; Payne S; Hartmann A; Latif F; Clark GJ
Mol Cell Biol; 2010 Jun; 30(11):2608-20. PubMed ID: 20368356
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanisms underlying the tumorigenesis of colorectal adenomas: correlation to activated K-ras oncogene.
Wang JY; Wang YH; Jao SW; Lu CY; Kuo CH; Hu HM; Hsieh JS; Chong IW; Cheng TL; Lin SR
Oncol Rep; 2006 Dec; 16(6):1245-52. PubMed ID: 17089045
[TBL] [Abstract][Full Text] [Related]
20. RASSF4/AD037 is a potential ras effector/tumor suppressor of the RASSF family.
Eckfeld K; Hesson L; Vos MD; Bieche I; Latif F; Clark GJ
Cancer Res; 2004 Dec; 64(23):8688-93. PubMed ID: 15574778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
